Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. Volkers AC, Tulen JH, van den Broek WW et al. Motor activity and autonomic cardiac functioning in major depressive disorder. J Affect Disord 2003; 76 (1–3): 23–30. 2. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol 2008; 23 (7): 571–85. 3. Wirz–Justice A, Campbell IC. Antidepressant drugs can slow or dissociate circadian rhythms. Experientia 1982; 38 (11): 1301–9. 4. Benca RM, Peterson MJ. Insomnia and depression. Sleep Med 2008; 9 (suppl. 1): 3–9. 5. Birchler–Pedross A, Schroder CM, Munch M et al. Subjective well-being is modulated by circadian phase, sleep pressure, age and gender. J Biol Rhythms 2009; 24 (3): 232–42. 6. Boivin DB, Czeisler CA, Dijk DJ et al. Complex interaction of the sleep-wake cycle and circadian phase modulates mood in healthy subjects. Arch Gen Psychiatry 1997; 54 (2): 145–52. 7. Zhou JN, Riemersma RF, Unmehopa UA et al. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001; 58 (7): 655–62. 8. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60 (suppl. 17): 28–31, discussion 46–8. 9. Judd LL, Akiskal HS, Maser JD et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50 (2–3): 97–108. 10. Cho HJ, Lavretsky H, Olmstead R et al. Sleep disturbance and depres¬sion recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry 2008; 165 (12): 1543–50. 11. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65 (7): 927–47. 12. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20 (8): 533–59. 13. Bauer M, Bschor T, Pfennig A et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8 (2): 67–104. 14. Rascati K. Drug utilization review of concomitant use of specific sero¬tonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther 1995; 17 (4): 786–90. 15. Jean–Louis G, Mendlowicz MV, Gillin JC et al. Sleep estimation from wrist activity in patients with major depression. Physiol Behav 2000; 70 (1–2): 49–53. 16. Raoux N, Benoit O, Dantchev N et al. Circadian pattern of motor ac¬tivity in major depressed patients undergoing antidepressant therapy: relationship between actigraphic measures and clinical course. Psychiatry Res 1994; 52 (1): 85–98. 17. Winkler D, Pjrek E, Praschak–Rieder N et al. Actigraphy in patients with seasonal affective disorder and healthy control subjects treated with light therapy. Biol Psychiatry 2005; 58 (4): 331–6. 18. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist ago-melatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306 (3): 954–64. 19. Yous S, Andrieux J, Howell HE et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992; 35(8): 1484–6. 20.Papp M, Gruca P, Boyer PA et al. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003; 28 (4): 694–703. 21. Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomela-tine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 2009; 10 (2): 117–26. 22. Fuchs E, Schmelting B, Mocaer E. Effects of the novel antidepressant ago-melatine (S 20098) and f1uoxetine in chronically stressed tree shrews, an animal model of depression. Eur Neuropsychopharmacol 2006; 16: 338. 23. Krauchi K, Cajochen C, Mori D et al. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997; 272 (4, Pt 2): 1178–88. 24. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16 (2): 93–100. 25. Loo H, Hale A, D\'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C-antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17 (5): 239–47. 26. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10 (5): 661–73. 27. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomela-tine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68 (11): 1723–32. 28. Kennedy SH, Rizvi S, Fulton K et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28 (3): 329–33. 29. Quera Salva MA, Vanier B, Laredo J et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10 (5): 691–6. 30. Hindmarch I, Bhatti JZ. Psychopharmacological effects of sertraline in normal, healthy volunteers. Eur J Clin Pharmacol 1988; 35 (2): 221–3. 31. Jindal RD, Friedman ES, Berman SR et al. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol 2003; 23 (6): 540–8. 32. Ancoli-Israel S, Cole R, Alessi C et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003; 26 (3): 342–92. 33. Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995; 10 (3): 129–41. 34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association 2000. 35. Sheehan DV, Lecrubier Y, Harnett Sheehan K et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997; 12 (5): 232–41. 36. Dodd A, Hare DJ, Arshad P. The use of melatonin to treat sleep disorder in adults with intellectual disabilities in community settings the evaluation of three cases using actigraphy. J Intellect Disabil Res 2008; 52 (6): 547–53. 37. Lahti TA, Haukka J, Lonnqvist J et al. Daylight saving time transitions and hospital treatments due to accidents or manic episodes. BMC Public Health 2008; 8 (1): 74. 38. Parrott AC, Hindmarch I. Factor analysis of a sleep evaluation questionnaire. Psychol Med 1978; 8 (2): 325–9. 39. Zisapel N, Nir T. Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. J Sleep Res 2003; 12 (4): 291–8. 40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23 (1): 56–62. 41. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32 (1): 50–5. 42. Guy W. ECDEU Assessment Manual for Psychopharmacology.US Dept Health, Education, and Welfare publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health 1976: 218–22. 43. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75 (4): 800–2. 44. Acebo C, LeBourgeois MK. Actigraphy. Respir Care Clin North Am 2006; 12 (1): 23–30. 45. Korszun A, Young EA, Engleberg NC et al. Use of actigraphy for monitoring sleep and activity levels in patients with fibromyalgia and depression. J Psychosom Res 2002; 52 (6): 439–43. 46. Rowe M, McCrae C, Campbell J et al. Actigraphy in older adults: comparison of means and variability of three different aggregates of measurement. Behav Sleep Med 2008; 6 (2): 127–45. 47. Sadeh A, Hauri PJ, Kripke DF et al. The role of actigraphy in the evaluation of sleep disorders. Sleep 1995; 18 (4): 288–302. 48. Saletu B, Grunberger J. Drug profiling by computed electroencephalo-graphy and brain maps, with special consideration of sertraline and its psychometric effects. J Clin Psychiatry 1988; 49: 59–71. 49. Goodwin GM, Emsley R, Rembry S. Agomelatine prevents relapse in patients with major depressive disorder, without evidence of a disconti uation syndrome. J Clin Psychiatry 2009; 70: 1128–37. 50. Kennedy SH, Guilleminault C. Antidepressant efficacy of agomelatine 25–50 mg versus venlafaxine 75–150 mg: two randomized, double-blind studies. Eur Neuropsychopharmacol 2006; 16: 319. 51. Hale A, Corral R, Mencacci R et al. Superior antidepressant efficacy of agomelatine vs fluoxetine in severe major depressive disorder pa¬tients: a randomised, double-blind study. Eur Neuropsychopharmacol 2009; 19: 418–9. 52. Cipriani A, Furukawa TA, Geddes JR et al. MANGA Study Group. Do randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? a systematic review and meta-analysis. J Clin Psychiatry 2008; 69 (11): 1732–42. 53. Santen G, Gomeni R, Danhof M et al. Sensitivity of the individual item of the Hamilton depression rating scale to response and its consequenc for the assessment of efficacy. J Psychiatr Res 2008; 42 (12): 1000–9. 54. Bech P, Gram LF, Dein E et al. Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51 (3): 161–70. 55. Melander H, Salmonson T, Abadie E et al. A regulatory apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008; 18 (9): 623–7. 56. Zisapel N, Laudon M. Subjective assessment of the effects of CNS-activ drugs on sleep by the Leeds Sleep Evaluation Questionnaire: a review. Hum Psychopharmacol 2003; 18 (1): 1–20. 57. Montejo A, Prieto N, Terleira A et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: an 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale [published online ahead of print November 21, 2008]. J Psychopharmacol.